PMID

Data

Article Title

Organization

Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH

Jagiellonian University Medical College

Ligands of the neuropeptide Y Y2 receptor.

The Scripps Research Institute

Design and Synthesis of Peptide YY Analogues with C-terminal Backbone Amide-to-Ester Modifications.

University Of Copenhagen

Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.

University Of Regensburg

Replacement of Thr32 and Gln34 in the C-terminal neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane β-amino acids shifts selectivity toward the Y(4) receptor.

University Of Regensburg

Heterocyclic modification of a novel bicyclo[3.1.0]hexane NPY1 receptor antagonist.

Bristol-Myers Squibb Research And Development

Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.

Institute Of Organic Synthesis

Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.

Universit£

Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.

Broad Institute Of Mit And Harvard

Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.

The Ohio State University

Synthesis and SAR of substituted tetrahydrocarbazole derivatives as new NPY-1 antagonists.

Glaxosmithkline

The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.

Glaxosmithkline

Discovery of a Novel Class of Bicyclo[3.1.0]hexanylpiperazines as Noncompetitive Neuropeptide Y Y1 Antagonists.

TBA

Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.

Pfizer

Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.

Aska Pharmaceutical

Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.

H. Lundbeck

5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor.

The University Of Mississippi

Discovery of novel orally active ureido NPY Y5 receptor antagonists.

Schering-Plough Research Institute

Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.

Salk Institute

Discovery of Lu AA33810: a highly selective and potent NPY5 antagonist with in vivo efficacy in a model of mood disorder.

Lundbeck Research Usa

Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.

Tsukuba Research Institute

Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools.

Universit£T Regensburg

Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists.

Pfizer

Spiroindolones, a potent compound class for the treatment of malaria.

Swiss Tropical And Public Health Institute

N(G)-Acyl-argininamides as NPY Y(1) receptor antagonists: Influence of structurally diverse acyl substituents on stability and affinity.

UniversitäT Regensburg

Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex-6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists.

Glaxosmithkline

A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.

Università

Discovery and SAR of cyclic isothioureas as novel NPY Y1 receptor antagonists.

Schering-Plough Research Institute

[Lys(DOTA)4]BVD15, a novel and potent neuropeptide Y analog designed for Y1 receptor-targeted breast tumor imaging.

Universit£

Identification of positron emission tomography ligands for NPY Y5 receptors in the brain.

Tsukuba Research Institute

Synthesis and evaluation of a series of 2,4-diaminopyridine derivatives as potential positron emission tomography tracers for neuropeptide Y Y1 receptors.

Tsukuba Research Institute

Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.

Tsukuba Research Institute

Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.

Tsukuba Research Institute

The identification and optimisation of novel and selective diamide neuropeptide Y Y2 receptor antagonists.

Glaxosmithkline

 

8-amino-6-(arylsulphonyl)-5-nitroquinolines: novel nonpeptide neuropeptide Y1 receptor antagonists

TBA

 

Novel Y₂-selective, reduced-size agonists of neuropeptide Y

TBA

Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.

Tsukuba Research Institute

Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.

Tsukuba Research Institute

Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and selective neuropeptide Y Y1 receptor antagonist.

University Of Regensburg

Modular synthesis of non-peptidic bivalent NPY Y1 receptor antagonists.

UniversitäT Regensburg

Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.

Banyu Tsukuba Research Institute

Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.

Banyu Tsukuba Research Institute

(9S)-9-(2-hydroxy-4,4-dimethyl-6-oxo-1-cyclohexen-1-yl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-xanthen-1-one, a selective and orally active neuropeptide Y Y5 receptor antagonist.

Tsukuba Research Institute

Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.

Bayer Pharmaceuticals

A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.

Bayer Pharmaceuticals

Novel carbazole derivatives as NPY Y1 antagonists.

Glaxosmithkline

Identification of selective neuropeptide Y2 peptide agonists.

Bayer Pharmaceuticals

Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar affinity.

University Of Cincinnati

Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists.

Bristol-Myers Squibb Pharmaceutical Research Institute

N-Terminus to Arginine Side-Chain Cyclization of Linear Peptidic Neuropeptide Y Y

University Of Regensburg

Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists.

Novartis Pharma

Synthesis and evaluation of substituted 4-alkoxy-2-aminopyridines as novel neuropeptide Y1 receptor antagonists.

Tsukuba Research Institute

Synthesis of new thiophene and benzo[b]thiophene hydrazide derivatives as human NPY Y(5) antagonists.

Universidad De Navarra

Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.

Syracuse University

Discovery of potent and selective small molecule NPY Y5 receptor antagonists.

Lundbeck Research Usa

Argininamide-type neuropeptide Y Y

University Of Regensburg

Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives.

Fujisawa Pharmaceutical

Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted benzo[a]cycloheptene derivatives.

Fujisawa Pharmaceutical

Dihydropyridine neuropeptide Y Y(1) receptor antagonists.

Pharmaceutical Research Institute

Novel dihydropyrazine analogues as NPY antagonists.

Bristol-Myers Squibb Pharmaceutical Research Institute

Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity.

The Scripps Research Institute

Synthesis and structure-activity relationships of trisubstituted phenyl urea derivatives as neuropeptide Y5 receptor antagonists.

Amgen

Oligopeptides as Neuropeptide Y Y

University Of Regensburg

Highly selective and potent neuropeptide Y (NPY) Y1 receptor antagonists based on [Pro(30), Tyr(32), Leu(34)]NPY(28-36)-NH2 (BW1911U90).

University Of Cincinnati And Va Medical Centers

High Affinity Agonists of the Neuropeptide Y (NPY) Y4 Receptor Derived from the C-Terminal Pentapeptide of Human Pancreatic Polypeptide (hPP): Synthesis, Stereochemical Discrimination, and Radiolabeling.

University Of Regensburg

Structure-activity studies including a Psi(CH(2)-NH) scan of peptide YY (PYY) active site, PYY(22-36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine.

University Of Cincinnati Medical Center

Structure-activity relationships of neuropeptide Y Y1 receptor antagonists related to BIBP 3226.

University Of Regensburg

Design, synthesis and SAR of a series of 2-substituted 4-amino-quinazoline neuropeptide Y Y5 receptor antagonists.

Novartis Pharma

Optically Pure, Structural, and Fluorescent Analogues of a Dimeric Y4 Receptor Agonist Derived by an Olefin Metathesis Approach.

Monash University (Parkville Campus)

Heterodimeric Analogues of the Potent Y1R Antagonist 1229U91, Lacking One of the Pharmacophoric C-Terminal Structures, Retain Potent Y1R Affinity and Show Improved Selectivity over Y4R.

Monash University (Parkville Campus)

1,3-Disubstituted benzazepines as novel, potent, selective neuropeptide Y Y1 receptor antagonists.

Shionogi

Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists.

Agouron Pharmaceuticals

Structure-activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y Y1 receptor antagonists.

Eli Lilly

Structure-activity relationships of a series of benzothiophene-derived NPY Y1 antagonists: optimization of the C-2 side chain.

Eli Lilly

Pharmacological treatment of obesity: therapeutic strategies.

The R. W. Johnson Pharmaceutical Research Institute

Structure-activity relationships of a series of 1-substituted-4-methylbenzimidazole neuropeptide Y-1 receptor antagonists.

Eli Lilly

Synthesis and evaluation of a series of novel 2-[(4-chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists.

Eli Lilly

Potent and selective 1,2,3-trisubstituted indole NPY Y-1 antagonists.

Eli Lilly

Bis(31/31') ([CYS(31), Trp(32), Nva(34)] NPY-(31-36)): a specific NPY Y-1 receptor antagonist.

University Of Cincinnati Medical Center

N(?)-Carbamoylation of the Argininamide Moiety: An Avenue to Insurmountable NPY Y1 Receptor Antagonists and a Radiolabeled Selective High-Affinity Molecular Tool ([(3)H]UR-MK299) with Extended Residence Time.

Cnrs/Ipbs (Institut De Pharmacologie Et Biologie Structurale)

Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.

Salk Institute

Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.

Salk Institute

Design of Y

TBA

Highly potent antiobesity effect of a short-length peptide YY analog in mice.

Takeda Pharmaceutical

Identification and biological evaluation of thiazole-based inverse agonists of ROR?t.

Phenex Pharmaceuticals

Identification and Characterization of the First Selective Y

Leipzig University

Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.

Meiji Seika Kaisha

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization.

Sanofi-Synthelabo Recherche

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Eli Lilly

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Eli Lilly

Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo.

Schering-Plough Research Institute

The first selective agonist for the neuropeptide YY5 receptor increases food intake in rats.

Federal Institute Of Technology Of Zurich

The cloned guinea pig neuropeptide Y receptor Y1 conforms to other mammalian Y1 receptors.

Uppsala University

SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Sanofi Recherche

Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.

Roche Bioscience

The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.

Synaptic Pharmaceutical

Cloning and functional expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and peptide YY.

Synaptic Pharmaceutical

Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype.

Synaptic Pharmaceutical